David Mountcastle Sells 6,565 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 6,565 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $21.52, for a total transaction of $141,278.80. Following the transaction, the chief financial officer owned 226,804 shares of the company’s stock, valued at approximately $4,880,822.08. This trade represents a 2.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

David Mountcastle also recently made the following trade(s):

• On Thursday, March 12th, David Mountcastle sold 6,453 shares of Privia Health Group stock. The stock was sold at an average price of $21.90, for a total transaction of $141,320.70.
• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The shares were sold at an average price of $22.84, for a total transaction of $133,134.36.
• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The stock was sold at an average price of $23.15, for a total transaction of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total transaction of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The shares were sold at an average price of $25.05, for a total value of $192,809.85.

Privia Health Group Price Performance

Shares of NASDAQ:PRVA traded up $0.28 on Monday, reaching $21.96. 633,287 shares of the company traded hands, compared to its average volume of 805,784. Privia Health Group, Inc. has a fifty-two week low of $18.77 and a fifty-two week high of $26.51. The company’s 50 day moving average is $22.89 and its 200-day moving average is $23.61. The stock has a market capitalization of $2.72 billion, a PE ratio of 129.18, a P/E/G ratio of 1.37 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.21. The business had revenue of $541.17 million for the quarter, compared to analysts’ expectations of $516.61 million. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The company’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.21 EPS. As a group, analysts expect that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Institutional Investors Weigh In On Privia Health Group

A number of institutional investors have recently modified their holdings of PRVA. Bayban purchased a new position in shares of Privia Health Group during the 4th quarter valued at $26,000. Invesco Ltd. raised its holdings in shares of Privia Health Group by 5.1% during the fourth quarter. Invesco Ltd. now owns 427,615 shares of the company’s stock worth $10,139,000 after acquiring an additional 20,652 shares in the last quarter. Wellington Management Group LLP boosted its position in Privia Health Group by 3.8% during the fourth quarter. Wellington Management Group LLP now owns 233,446 shares of the company’s stock valued at $5,535,000 after purchasing an additional 8,531 shares during the last quarter. Millennium Management LLC boosted its position in Privia Health Group by 19.0% during the fourth quarter. Millennium Management LLC now owns 702,744 shares of the company’s stock valued at $16,662,000 after purchasing an additional 112,428 shares during the last quarter. Finally, Gotham Asset Management LLC grew its stake in Privia Health Group by 22.4% in the fourth quarter. Gotham Asset Management LLC now owns 36,995 shares of the company’s stock valued at $877,000 after purchasing an additional 6,773 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Citigroup dropped their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $36.00 price objective on shares of Privia Health Group in a research note on Thursday, February 26th. Royal Bank Of Canada began coverage on shares of Privia Health Group in a report on Friday, January 9th. They issued an “outperform” rating and a $31.00 target price for the company. Truist Financial lifted their target price on shares of Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Wolfe Research set a $31.00 price target on shares of Privia Health Group in a report on Tuesday, January 6th. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.